Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506.

Literature DB >> 2481200

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506.

J McCauley, O Bronsther, J Fung, S Todo, T E Starzl.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 1989 PMID： 2481200 PMCID： PMC3095826 DOI： 10.1016/s0140-6736(89)92951-6

Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321

× No keyword cloud information.

7 in total

1. Cyclosporine induced hemolytic anemia in a liver transplant patient.

Authors: J L Faure; X Causse; A Bergeret; F Meyer; J Neidecker; P Paliard
Journal: Transplant Proc Date: 1989-02 Impact factor: 1.066

2. FK 506 for liver, kidney, and pancreas transplantation.

Authors: T E Starzl; S Todo; J Fung; A J Demetris; R Venkataramman; A Jain
Journal: Lancet Date: 1989-10-28 Impact factor: 79.321

Review 3. Cyclosporine in cardiac transplantation.

Authors: M H Goldman; G Barnhart; T Mohanakumar; L Wetstein; S Szentpetery; T C Wolfgang; R R Lower
Journal: Surg Clin North Am Date: 1985-06 Impact factor: 2.741

4. De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine.

Authors: D Van Buren; C T Van Buren; S M Flechner; A M Maddox; R Verani; B D Kahan
Journal: Surgery Date: 1985-07 Impact factor: 3.982

5. Cyclosporin-induced endothelial cell injury.

Authors: C Zoja; L Furci; F Ghilardi; P Zilio; A Benigni; G Remuzzi
Journal: Lab Invest Date: 1986-10 Impact factor: 5.662

6. Identification and treatment of cyclosporine-associated allograft thrombosis.

Authors: R E Schlanger; M L Henry; B G Sommer; R M Ferguson
Journal: Surgery Date: 1986-08 Impact factor: 3.982

7. Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes.

Authors: K Atkinson; J C Biggs; J Hayes; M Ralston; A J Dodds; A J Concannon; D Naidoo
Journal: Br J Haematol Date: 1983-05 Impact factor: 6.998

7 in total

9 in total

1. Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome.

Authors: J McCauley; R Shapiro; O Bronster; M Jordan; D Ellis; N Gilboa; V Scantlebury; C Jensen; A Jain; T Starzl
Journal: Transplant Proc Date: 1991-12 Impact factor: 1.066

2. Use of FK 506 in pediatric patients.

Authors: A G Tzakis; J J Fung; S Todo; J Reyes; M Green; T E Starzl
Journal: Transplant Proc Date: 1991-02 Impact factor: 1.066

3. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine.

Authors: P S Randhawa; R Shapiro; M L Jordan; T E Starzl; A J Demetris
Journal: Am J Surg Pathol Date: 1993-01 Impact factor: 6.394

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506.

1. Cyclosporine induced hemolytic anemia in a liver transplant patient.

2. FK 506 for liver, kidney, and pancreas transplantation.

Review 3. Cyclosporine in cardiac transplantation.

4. De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine.

5. Cyclosporin-induced endothelial cell injury.

6. Identification and treatment of cyclosporine-associated allograft thrombosis.

7. Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes.

1. Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome.

2. Use of FK 506 in pediatric patients.

3. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine.

4. Tacrolimus (FK506)-Associated Renal Pathology.

5. Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy.

6. Kidney transplantation under FK 506.

7. FK 506 prevents spontaneous diabetes in the BB rat.

Review 8. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.

Review 9. Recurrent primary disease and de novo nephritis following renal transplantation.